SYK and primary cutaneous T-cell non-Hodgkin lymphoma: Cerdulatinib can also block the cell cycle by inhibiting RB phosphorylation and down-regulating cyclin E. As a dual inhibitor of JAK and SYK pathways, cerdulatinib has shown efficacy in patients with r/r PTCL or CTCL [36].